On this episode, we review the management of amyotrophic lateral sclerosis (ALS). We discuss riluzole, edaravone, and sodium phenylbutyrate-taurursodiol (Relyvrio) that gained FDA approval in September 2022.

Thanks for listening!

We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial:

www.pyrls.com/corconsultrx

If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:

www.patreon.com/corconsultrx

If you have any questions for Cole or me, reach out to us on any of the following:

Text - 415-943-6116

Mike - mcorvino@corconsultrx.com
Cole - cswanson@corconsultrx.com

Instagram and other social media platforms - @corconsultrx

This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.

свернуть